ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2026 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 8.830-9.340 for the period, compared to the consensus estimate of 7.900. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.0 billion.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Guggenheim upped their price objective on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Finally, Barclays started coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 target price for the company. Six investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $103.43.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $76.53 on Thursday. The company’s 50 day moving average price is $79.92 and its 200 day moving average price is $86.11. ANI Pharmaceuticals has a 52 week low of $56.71 and a 52 week high of $99.50. The company has a market capitalization of $1.72 billion, a PE ratio of 22.78 and a beta of 0.52. The company has a debt-to-equity ratio of 1.11, a quick ratio of 2.19 and a current ratio of 2.71.

Insider Activity

In other news, SVP Ori Gutwerg sold 2,060 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $76.50, for a total transaction of $157,590.00. Following the completion of the sale, the senior vice president directly owned 84,782 shares in the company, valued at $6,485,823. The trade was a 2.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Christopher Mutz sold 417 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $74.00, for a total value of $30,858.00. Following the completion of the transaction, the insider owned 103,508 shares in the company, valued at $7,659,592. This represents a 0.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 15,936 shares of company stock valued at $1,255,059. 11.10% of the stock is currently owned by company insiders.

Key Headlines Impacting ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI raised FY2026 guidance well above consensus: adjusted EPS guidance of 8.83–9.34 vs. a 7.90 consensus, and revenue guidance around $1.1 billion vs. ~ $1.0 billion consensus — a clear beat that supports higher valuation and stronger forward expectations.
• Positive Sentiment: Guggenheim reiterated its Buy rating on ANIP, which can boost investor confidence and buying interest following the upbeat guidance. Guggenheim reiteration
• Neutral Sentiment: Short-interest reports show 0 shares and a 0.0 days-to-cover ratio for early March — this is likely a data/reporting glitch rather than a real increase in shorts; treat these figures with caution until corrected.
• Negative Sentiment: Two insider sell transactions were disclosed this week: SVP Ori Gutwerg sold 2,060 shares at an average price of $76.50 (≈$157.6k) and insider Christopher Mutz sold 417 shares at $74.00 (≈$30.9k). These are modest reductions in insider positions but can be perceived as incremental selling pressure or profit-taking. Gutwerg Form 4 Mutz Form 4

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of large investors have recently bought and sold shares of ANIP. Arrowstreet Capital Limited Partnership acquired a new position in ANI Pharmaceuticals during the third quarter worth $32,992,000. Balyasny Asset Management L.P. boosted its stake in shares of ANI Pharmaceuticals by 2,785.7% during the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock worth $26,211,000 after acquiring an additional 276,233 shares in the last quarter. Rubric Capital Management LP raised its stake in shares of ANI Pharmaceuticals by 354.7% in the 2nd quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock valued at $16,813,000 after acquiring an additional 200,998 shares in the last quarter. UBS Group AG raised its stake in shares of ANI Pharmaceuticals by 45.8% in the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after acquiring an additional 185,172 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC lifted its holdings in ANI Pharmaceuticals by 780.8% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 192,006 shares of the specialty pharmaceutical company’s stock worth $15,157,000 after purchasing an additional 170,206 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.